Respiratory Muscle Strength in Volleyball Players Suffered From COVID-19

Sponsor

Gazi University (Other)

Overall Status

Completed

CT.gov ID

NCT04789512

Collaborator

(none)

Enrollment

Location

Actual Duration (Days)

45.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

In literature, there is no data evaluating respiratory functions in volleyball players during Covid-19 pandemic. The aim of this study is to evaluate and compared pulmonary functions, respiratory muscle strength, body compositions and performance situations perceptions in female volleyball players with Covid-19 and non-Covid-19.

Condition or Disease	Intervention/Treatment	Phase
Covid19	Other: Respiratory functions

Study Design

Study Type:

Observational

Actual Enrollment :

42 participants

Observational Model:

Case-Control

Time Perspective:

Prospective

Official Title:

Evaluation of Respiratory Muscle Strength and Pulmonary Functions in Volleyball Players Suffering From Covid-19

Actual Study Start Date :

Mar 1, 2021

Actual Primary Completion Date :

Mar 26, 2021

Actual Study Completion Date :

Mar 29, 2021

Arms and Interventions

Arm	Intervention/Treatment
Covid-19 players Female volleyball players with Covid-19	Other: Respiratory functions Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players
non-Covid-19 players Female volleyball players with non Covid-19	Other: Respiratory functions Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players

Arm

Intervention/Treatment

Covid-19 players

Female volleyball players with Covid-19

Other: Respiratory functions

Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players

non-Covid-19 players

Female volleyball players with non Covid-19

Other: Respiratory functions

Respiratory muscle strength, pulmonary functions and body composition were evaluated in volleyball players

Outcome Measures

Primary Outcome Measures

Respiratory muscle strength [10 minute]
Maximal inspiratory and expiratory muscle strength will be evaluated using mouth pressure device.

Secondary Outcome Measures

FEV1 [5 minute]
Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1 will be evaluated. The percentage of predicted value <70% will be expressed as abnormal.
FVC [5 minute]
Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FVC will be evaluated. The percentage of predicted value <70% will be expressed as abnormal
FEV1/FVC [5 minute]
Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEV1/FVC will be evaluated.
PEF [5 minute]
Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. PEF will be evaluated. The percentage of predicted value <70% will be expressed as abnormal.
FEF2575 [5 minute]
Pulmonary function tests will be performed using a spirometry according to the American Thoracic Society and European Respiratory Society criteria. FEF2575 will be evaluated. The percentage of predicted value <50% will be expressed as abnormal.
Fat mass [2 minute]
Fat mass will be evaluated using TANITA bioelectrical impedance analysis.
Fat mass percent [2 minute]
Fat mass percent will be evaluated using TANITA bioelectrical impedance analysis.
Fat-free mass [2 minute]
Fat-free mass will be evaluated using TANITA bioelectrical impedance analysis.
Body mass index [2 minute]
Body mass index will be evaluated using TANITA bioelectrical impedance analysis.
Predicted muscle mass [2 minute]
Predicted muscle mass will be evaluated using TANITA bioelectrical impedance analysis.
Symptom severity perceptions [1 minute]
Symptom severity perceptions will be evaluated Numeric Rating Scale.The severity of symptoms perceptions related to Covid are scored 0-10 point. Higher scores indicate higher severity of symptoms.
Performance situations perceptions [1 minute]
Performance situations perceptions will be evaluated Numeric Rating Scale. Performance situations perceptions of all players are also scored 0-10 point. Higher scores indicate greater performance.

Eligibility Criteria

Criteria

Ages Eligible for Study:

15 Years to 35 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

having passed at least 30 days after the Polymerase Chain Reaction (PCR) test turned negative
willing to participate in the study

Exclusion Criteria:

having a history of chronic lung disease
unwilling to participate in the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Gazi University	Ankara	Çankaya	Turkey	06490

Sponsors and Collaborators

Gazi University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Zeliha ÇELİK, Research assistant, Gazi University

ClinicalTrials.gov Identifier:

NCT04789512

Other Study ID Numbers:

2021-189

First Posted:

Mar 9, 2021

Last Update Posted:

Apr 1, 2021

Last Verified:

Mar 1, 2021

Individual Participant Data (IPD) Sharing Statement:

Yes

Plan to Share IPD:

Yes

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by Zeliha ÇELİK, Research assistant, Gazi University

respiratory muscles

pulmonary functions

Additional relevant MeSH terms:

COVID-19

Study Results

No Results Posted as of Apr 1, 2021